NASDAQ · AGEN
Healthcare · Biotechnology
$6.16
Down-$0.17 (-2.69%)
Updated Oct 27, 2026, 12:46 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AGEN
1M range · 0 trading sessions · Daily adjusted prices
AGEN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning AGEN.
Company
Market Activity
Research & News
AGEN research
Company profile and research snapshot.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 26, 2026 | Chardan Capital | Buy | — |
| Oct 22, 2026 | Chardan Capital | Buy | — |
| Oct 5, 2026 | Chardan Capital | Buy | — |
| Sep 28, 2026 | Rodman & Renshaw | Buy | — |
| Sep 18, 2026 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 20, 2026
Agenus (NASDAQ:AGEN) is concentrating its registration strategy for BOT/BAL on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III microsatellite-stable (MSS) colon cancer, after ending funding for its BATTMAN study in later-line metastatic disease. Zack Armen, Agenus’ vice preside
Yahoo · Oct 9, 2026
LEXINGTON, Mass., October 09, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardan’s 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation, on October 20, 2026.
Yahoo · Oct 8, 2026
LEXINGTON, Mass., October 08, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases who have previously received ava
Benzinga · Oct 8, 2026
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGEN.
